Top

Journal of Endocrinological Investigation

Published in:

01-08-2015 | Original Article

Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate

Authors: A. Catalano, N. Morabito, A. Di Stefano, E. Morini, G. Basile, B. Faraci, S. Loddo, R. Ientile, A. Lasco

Published in: Journal of Endocrinological Investigation | Issue 8/2015

Abstract

Objective

Vitamin D deficiency is widespread and often reported in subjects treated for osteoporosis. Optimal vitamin D repletion was previously shown to maximize the efficacy of anti-resorptive agents. To date, no information exists about the role of vitamin D in the response to strontium ranelate (SrR) treatment. The aim of our study was to investigate the BMD response to SrR in accordance with change of vitamin D status.

Methods

A retrospective analysis of 108 women receiving SrR for postmenopausal osteoporosis was carried out. Women were treated with SrR (2 g/day), with cholecalciferol (25,000 IU biweekly) and calcium carbonate as appropriate. Lumbar spine and femoral neck BMD, bone formation markers (BGP, ALP), resorption marker (OH-PRO) and serum 25(OH)D were measured at baseline after 18-months. All participants were divided into two groups according to the median variation of 25(OH)D over the observation period.

Results

SrR was associated with improvement of BMD at lumbar spine (p < 0.0001) and to a non significant variation at femoral neck (p = 0.2). Only subjects with Δ25(OH)D > 6.14 %, reported a significant BMD gain at femoral neck (p = 0.03). Change of BMD at femoral neck was positively associated with modification of ALP (r = 0.28, p = 0.01). This association was not maintained when considering only women with Δ25(OH)D < 6.14 % (r = 0.28, p = 0.09). At a multiple regression analysis, ALP change was the only predictor of femoral neck BMD modification (β 0.13; SE 0.05; p = 0.01).

Conclusion

Improvement of vitamin D status was associated with enhancement of BMD response to SrR in women with postmenopausal osteoporosis, in particular, at femoral neck.

Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Oteoporos Int 14:577–582CrossRef

Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062–2072PubMedCentralPubMedCrossRef

Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRef

Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE (2005) Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215–3224PubMedCrossRef

Romagnoli E, Carnevale V, Biondi P, Minisola S (2014) Vitamin D supplementation: when and how? J Endocrinol Invest 37(7):603–607PubMedCrossRef

Reid IR (2014) Effects of vitamin D supplements on bone density. J Endocrinol Invest (Epub ahead of print)

Cipriani C, Romagnoli E, Carnevale V, Clerico R, Pepe J, Cilli M, Diacinti D, Savoriti C, Colangelo L, Minisola S (2013) Effect of a single oral dose of 600,000 IU of cholecalciferol on muscle strength: a study in young women. J Endocrinol Invest 36(11):1051–1054PubMed

Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20(2):239–244PubMedCrossRef

Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is 33 ng/mL. Osteoporos Int 23(10):2479–2487PubMedCentralPubMedCrossRef

10.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski J, Spector T, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef

11.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef

12.

Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98(2):592–601PubMedCrossRef

13.

Marie PJ, Ammann P, Boivin G, Rey C (2001) Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129PubMedCrossRef

14.

Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21(10):1565–1570PubMedCrossRef

15.

Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85(1):231–236PubMedCrossRef

16.

Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23:3041–3045PubMedCrossRef

17.

Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076–3081PubMedCrossRef

18.

Marcelli C, Chavoix C, Dargent-Molina P (2015) Beneficial effects of vitamin D on falls and fractures: is cognition rather than bone or muscle behind these benefits? Osteoporos Int 26(1):1–10PubMedCrossRef

19.

Poole CD, Smith JC, Davies JS (2014) The short-term impact of vitamin D-based hip fracture prevention in older adults in the United Kingdom. J Endocrinol Invest 37(9):811–817PubMedCrossRef

20.

Reid IR, Bolland MJ, Grey A (2014) Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383:146–155PubMedCrossRef

21.

Vilaca T, Camargo MB, Rocha OF, Lazaretti-Castro M (2014) Vitamin D supplementation and strontium ranelate absorption in postmenopausal women with low bone mass. Eur J Endocrinol 170(4):469–475PubMedCrossRef

22.

Ishtiaq S, Fogelman I, Hampson G. (2014) Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Invest (Epub ahead of print)

23.

Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Muxi A, Guañabens N (2012) 25-hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51(1):54–55PubMedCrossRef

24.

Abboskhujaeva LS, Ismailov SI, Alikhanova NM (2014) Efficacy of strontium ranelate in combination with a d-hormone analog for the treatment of postmenopausal osteoporosis. Drugs R D 14(4):315–324PubMedCentralPubMedCrossRef

25.

European Medicines Agency (2013) protelos-H-C-560-PSU-31: EPAR-assessment report-periodic safety update report

26.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4):503–511PubMedCrossRef

Title: Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate
Authors: A. Catalano
N. Morabito
A. Di Stefano
E. Morini
G. Basile
B. Faraci
S. Loddo
R. Ientile
A. Lasco
Publication date: 01-08-2015
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 8/2015
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0299-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2015

Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings

Sleep apnea syndrome in endocrine clinics

Total thyroid ablation in Graves’ orbitopathy

Effects of monobutyl phthalate on steroidogenesis through steroidogenic acute regulatory protein regulated by transcription factors in mouse Leydig tumor cells

Association between nonalcoholic fatty liver disease and bone mineral density: a systematic review and meta-analysis

An efficient case finding strategy to diagnose osteoporosis in a developing society with low treatment frequency

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials